Unlocking the Potential of HSD17B4: A D-Bifunctional Protein as a Drug Target and Biomarker

Target Name: HSD17B4

NCBI ID: G3295

HSD17B4

Unlocking the Potential of HSD17B4: A D-Bifunctional Protein as a Drug Target and Biomarker

Peroxisomes are organelles that are responsible for the detoxification of harmful substances, such as xenobiotics, in the body. Peroxisomes are also involved in the production of malononitrile, a metabolite that can cause damage to cells and organs if it accumulates in the body. The hsp70 gene family, which encodes the peroxisomal protein HSD17B4, is a key regulator of peroxisomal function. In this article, we will explore the potential of HSD17B4 as a drug target and biomarker.

HSD17B4: A D-Bifunctional Protein

HSV-17B4 (Human Serine Vertebrae-associated Protein 17B4) is a 16kDa protein that is expressed in the peroxisomal fraction of the brain. It is one of the four major classes of peroxisomal proteins, which include HSP70, HSP76, HSP90, and HSP162. HSD17B4 is characterized by its unique D-type transmembrane domain, which gives it its unique structure and function.

The D-type transmembrane domain is a structural feature that is common in many proteins that are involved in signaling and cell adhesion. It consists of a long alpha-helices that are involved in the formation of a hydrophobic core, as well as a short beta-sheet that is involved in the formation of a hydrophilic interior. The D-type transmembrane domain is responsible for the regulation of peroxisomal function, as well as the detoxification of harmful substances in the body.

HSD17B4 functions as a bifunctional protein that is involved in both peroxisomal and non-peroxisomal processes. One of its functions is to regulate the peroxisomal import of metabolites, such as malononitrile, into the peroxisome. This is accomplished through its interaction with the transmembrane domain of HSP70, which is responsible for the recognition and import of metabolites into the peroxisome.

Another function of HSD17B4 is its role in the detoxification of harmful substances in the body. Malononitrile is a metabolite that is produced by the body and can cause damage to cells and organs if it accumulates in the body. HSD17B4 is involved in the detoxification of malononitrile by forming a complex with HSP70, which facilitates its excretion from the body.

HSD17B4 as a Drug Target

The unique function of HSD17B4 as a peroxisomal and non-peroxisomal regulator has led to its potential as a drug target. One of the main goals of drug development is to identify and intervene in the functions of specific proteins that are involved in disease. HSD17B4 is an attractive target for drug development due to its involvement in both peroxisomal and non-peroxisomal processes, as well as its unique structure and function.

HSD17B4 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, studies have shown that HSD17B4 is involved in the development and progression of colon cancer by regulating the peroxisomal function of cancer cells. Additionally, HSD17B4 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by regulating the functions of neurons and glial cells.

Another potential mechanism by which HSD17B4 may contribute to

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 4

Functions: Bifunctional enzyme acting on the peroxisomal fatty acid beta-oxidation pathway. Catalyzes two of the four reactions in fatty acid degradation: hydration of 2-enoyl-CoA (trans-2-enoyl-CoA) to produce (3R)-3-hydroxyacyl-CoA, and dehydrogenation of (3R)-3-hydroxyacyl-CoA to produce 3-ketoacyl-CoA (3-oxoacyl-CoA), which is further metabolized by SCPx. Can use straight-chain and branched-chain fatty acids, as well as bile acid intermediates as substrates

The "HSD17B4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets